Summary

BLG is committed to helping its clients effectively and responsibly navigate Canada’s move from prohibition to regulation of cannabis. Our commitment is mirrored by our attention to the rapidly evolving cannabis industry, which is uniquely regulated federally across Canada, locally within provinces and municipalities, and in jurisdictions beyond our borders.

BLG’s multi-disciplinary cannabis industry focus group is at the forefront of Canadian legal service providers. We provide first-in-class corporate, securities, regulatory, advertising, privacy, technology, tax, intellectual property, commercial real estate, employment and litigation counsel. BLG is continuously involved in corporate transactions and advisory services across all cannabis industry subsections.

Publications & Presentations

Publications & Presentations

Client Bulletins

Publications & Presentations

Representative Work

Corporate and Securities Transactions

BLG has advised in respect of brokered and non-brokered debt and equity financing, mergers and acquisitions, initial public offerings and other going-public transactions. Recent experience includes acting as counsel in respect of: 

  • CanniMed Therapeutics Inc., in its contest for control with Aurora Cannabis, including hearings before the Ontario and Saskatchewan securities commissions, and favourable resolution; its proposed and abandoned acquisition of Newstrike Resources Ltd., by way of a share exchange and its prior $60 million initial public offering. CanniMed was only the second medical cannabis company to list on the TSX, and its IPO was one of only three IPO’s on the TSX in 2016.
  • Sunniva Inc., in connection with its initial public offering and listing of its shares on the Canadian Securities Exchange, and, prior to the IPO, its three acquisitions and a series of private placement financings with an aggregate value of approximately $40 million.
  • The agents, in connection with a $125 million offering of subscription receipts of MedMen Enterprises Inc., in connection with its listing on the Canadian Securities Exchange by way of a reverse take-over.
  • Terra Life Sciences, a company involved in R&D of innovative cannabis-derived medical products, in connection with a $46 million private placement of convertible debentures.
  • The agents, in connection with a $10.5 million private placement of convertible debentures by Cardiol Therapeutics Inc., a nanotherapeutics company developing proprietary formulations designed to deliver cannabinoids and other drugs.
  • Brassneck Capital Corp., in connection with its IPO on the TSX Venture Exchange, by way of a reverse take-over by National Access Cannabis Corp.
  • The underwriters, in connection with the $52 million bought deal offering of common shares of Nuuvera Inc.
  • The agents, in connection with a $19 million offering of subscription receipts of a Canadian-based licensed producer that also holds licenses for the production, processing and wholesale distribution of cannabis in the U.S., in connection with its upcoming listing on the Canadian Securities Exchange by way of a reverse take-over.
  • The underwriters, in connection with multiple public offerings and bought deals of shares of Aphria Inc., a licensed producer, raising aggregate proceeds of approximately $670 million.
  • The underwriter, in connection with a $14 million bought deal offering of units of InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the R&D of cannabinoid-based prescription drug therapies.
  • The underwriters, in connection with the $27 and $17 million bought deal offerings of shares of Emerald Health Therapeutics Inc., a licensed producer.
  • Maple Leaf Green World Inc., a Canadian licensed producer with operations in Nevada, in connection with its $7.3 million private placement
  • The agents, in connection with the $10 million private placement of subscription receipts of CannaRoyalty Corp. in connection with CannaRoyalty’s three-cornered amalgamation with Cannabis Royalties & Holdings Corp. CannaRoyalty is a royalty company providing financing for companies in the cannabis ecosystem.
  • The agents, in connection with a series of private placements of shares of Lexaria Bioscience Corp., with an aggregate value of approximately $5 million.
  • The agents, in connection with the $35 million private placement of subscription receipts of DFMMJ Investments Inc. in connection with DFMMJ’s three-cornered amalgamation with SecureCom Corp. DFMMJ, doing business as "Aphria USA", is a licensed producer in Florida.
  • Green Relief Inc., in connection with its $20 million private placement of convertible debentures.

Ongoing Advisory

BLG’s cannabis industry focus group has breadth and depth of experience in advising a variety of industry participants, both domestic and foreign, in relation to operating within the Canadian medical cannabis market and the adult use market. Recent and ongoing examples include: 

  • Advising entities at all stages of ACMPR license applications, including corporate, securities, regulatory, tax, intellectual property, commercial real estate, employment and litigation counsel;
  • Advising international pharmaceutical companies in relation to cannabis supply, regulatory compliance, intellectual property and dosage forms;
  • Advising a national pharmacy chain in relation to cannabis supply, regulatory compliance, intellectual property, e-commerce and new product categories;
  • Advising a payment processor in respect of working with LPs;
  • Advising a natural health products company in relation to ACMPR licensing and intellectual property;
  • Advising a food company in relation to the ACMPR, the NCR, and other aspects of positioning itself for sale of infused foods and beverages when those products are regulated for sale;
  • Advising multiple technology companies (domestic and foreign), including NCR licensed dealers and ACMPR applicants, in relation to: 
    • wholesale cannabis supply agreements;
    • scope of activities under ACMPR licenses, NCR licenses, and Marihuana Medical Access Regulations licenses extended by R v Allard;
    • importation and exportation of cannabis under the ACMPR and the NCR;
    • intellectual property licensing;
    • patent rights, including drafting and filing patent applications in relation to biotechnology and dosage forms;
    • plant breeder’s rights and trade secrets;
    • the scope of wares and services that may be included in trademark applications to position for adult use and for product diversity;
  • Drafting website terms and conditions, drafting a privacy policy, and advising in relation to advertising for LPs and social media companies;
  • Advising an assisted living facility in relation to the scope of practice of nurses outside of hospitals, and in relation to a post-Cannabis Act adult use policy;
  • Immigrating skilled individuals to Canada for work in the cannabis industry; and
  • Advising in respect of employment law matters and employee drug testing.